Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules?
---- Acknowledgements ----
This research has been supported by Pfizer, Inc., whose support we gratefully acknowledge. We also acknowledge with thanks the extensive data support from and discussions with Michael Kleinrock of IMS Health, and superb research assistance from Lauren Trusheim. Any opinions expressed herein are those of the authors, and do not necessarily reflect the views and judgments of the sponsor or the institutions with whom the authors are affiliated or the National Bureau of Economic Research. Presented at the National Bureau of Economic Research Workshop on Frontiers in Health Policy Research, Washsington DC, October 14, 2009. Forthcoming, Forum for Health Economics & Policy.